Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | HTR1A | P08908 | 1/20 | 0.30 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.30 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.30 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.30 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.30 |
| ▸ | HTR1D | P28221 | 1/20 | 0.30 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
| ▸ | HTR1E | P28566 | 1/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.30 |
| ▸ | HRH1 | P35367 | 1/20 | 0.30 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.30 |
| ▸ | DRD3 | P35462 | 1/20 | 0.30 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.30 |
| ▸ | HTR2B | P41595 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3480656 | 0.92 | KDM4E (0.32) | KDM4EMEN1KMT2ASMN1; SMN2HTR1A | |
| SCHEMBL213436 | 0.89 | ALDH1A1 (0.35) | KDM4EMEN1KMT2ASMN1; SMN2HTR1A | |
| SCHEMBL3060057 | 0.86 | KDM4E (0.33) | KDM4EMEN1KMT2ASMN1; SMN2HTR1A | |
| SCHEMBL6943640 | 0.86 | KDM4E (0.33) | KDM4EMEN1KMT2ASMN1; SMN2HTR1A | |
| SCHEMBL3655351 | 0.86 | KDM4E (0.33) | KDM4EMEN1KMT2ASMN1; SMN2HTR1A | |
| SCHEMBL4042670 | 0.84 | TSHR (0.38) | ALDH1A1 | |
| Hydrochloric Acid SCHEMBL11141982 | 0.83 | OPRK1 (0.33) | KDM4EMEN1KMT2ASMN1; SMN2HTR1A | |
| SCHEMBL2699253 | 0.83 | ALDH1A1 (0.35) | KDM4EMEN1KMT2ASMN1; SMN2HTR1A | |
| SCHEMBL6527091 | 0.80 | OPRK1 (0.35) | KDM4EMEN1KMT2ASMN1; SMN2HTR1A | |
| SCHEMBL192060 | 0.80 | KDM4E (0.33) | KDM4EMEN1KMT2ASMN1; SMN2HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 733 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023105303-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER | KASHIV BIOSCIENCES, LLC (US) | 2023-06-15 | — | — | WO | claimed |
| EP-3344623-B1 | IMIDAZO[4,5-C]RING COMPOUNDS CONTAINING SUBSTITUTED GUANIDINE GROUPS | 3M INNOVATIVE PROPERTIES CO (US) | 2021-02-17 | — | — | EP | claimed |
| US-10766896-B2 | Imidazo[4,5-c] ring compounds containing guanidine substituted benzamide groups | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2020-09-08 | — | — | US | claimed |
| US-20200087298-A1 | Imidazo[4,5-c] Ring Compounds Containing Guanidine Substituted Benzamide Groups | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | 2020-03-19 | — | — | US | claimed |
| US-10118925-B2 | Imidazo[4,5-c] ring compounds containing substituted guanidine groups | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2018-11-06 | — | — | US | claimed |
| US-10113978-B2 | Method for measuring solid-liquid interfacial electric field | EASTMAN KODAK COMPANY (US) | 2018-10-30 | — | — | US | claimed |
| WO-2018160552-A1 | IMIDAZO[4,5-c] RING COMPOUNDS CONTAINING GUANIDINE SUBSTITUTED BENZAMIDE GROUPS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2018-09-07 | — | — | WO | claimed |
| US-20180244669-A1 | IMIDAZO[4,5-c] RING COMPOUNDS CONTAINING SUBSTITUTED GUANIDINE GROUPS | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | 2018-08-30 | — | — | US | claimed |
| US-10060853-B2 | Method for determining a characteristics difference between fluids | EASTMAN KODAK COMPANY (US) | 2018-08-28 | — | — | US | claimed |
| US-10054544-B2 | Method for characterizing a liquid | EASTMAN KODAK COMPANY (US) | 2018-08-21 | — | — | US | claimed |
| CN-1227217-C | End-capped polyfluorenes, films and devices based thereon | SONY INT EUROPE GMBH (DE) | 2005-11-16 | — | — | CN | claimed |
| EP-1054886-B1 | HETEROARYL AMIDINES, METHYLAMIDINES AND GUANIDINES AS PROTEASE INHIBITORS, IN PARTICULAR AS UROKINASE INHIBITORS | DIMENSIONAL PHARM INC (US) | 2002-09-04 | — | — | EP | claimed |
| CN-1366516-A | End-capped polyfluorenes, films and devices based thereon | SONY INT EUROPE GMBH (DE) | 2002-08-28 | — | — | CN | claimed |
| EP-1150979-A1 | HETEROARYL AMIDINES, METHYLAMIDINES AND GUANIDINES AS PROTEASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2001-11-07 | — | — | EP | claimed |
| US-20010031781-A1 | Heteroaryl amidines, methylamidines and guanidines and use thereof as protease inhibitors | ILLIG CARL R (US) | 2001-10-18 | — | — | US | claimed |
| EP-1054886-A1 | HETEROARYL AMIDINES, METHYLAMIDINES AND GUANIDINES AS PROTEASE INHIBITORS, IN PARTICULAR AS UROKINASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2000-11-29 | — | — | EP | claimed |
| WO-2000047578-A1 | HETEROARYL AMIDINES, METHYLAMIDINES AND GUANIDINES AS PROTEASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2000-08-17 | — | — | WO | claimed |
| WO-1999040088-A1 | HETEROARYL AMIDINES, METHYLAMIDINES AND GUANIDINES AS PROTEASE INHIBITORS, IN PARTICULAR AS UROKINASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 1999-08-12 | — | — | WO | claimed |
| EP-0533244-B1 | Amide-substituted derivatives of spiroindanylcamphorsulfonyl oxytocin antagonists | MERCK & CO INC (US) | 1997-12-17 | — | — | EP | claimed |
| EP-0056574-B1 | NAPHTHALENESULFONIC ACID COMPOUNDS, THEIR PREPARATION AND USE AS COUPLING COMPONENTS | BAYER AG (DE) | 1985-03-13 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10118925-B2 | Imidazo[4,5-c] ring compounds containing substituted guanidine groups | IFNG, IRF3, IL4 | KDM4E 1171/4885MEN1 3771/4885KMT2A 3849/4885 |
| US-20200087298-A1 | Imidazo[4,5-c] Ring Compounds Containing Guanidine Substituted Benzamide Groups | IL4, IFNG, IFNAR1 | KDM4E 1023/4885MEN1 3262/4885KMT2A 3064/4885 |
| US-20010031781-A1 | Heteroaryl amidines, methylamidines and guanidines and use thereof as protease inhibitors | SERPINE1, PRSS3, PRSS2 | KDM4E 3095/4885MEN1 2168/4885KMT2A 2992/4885 |
| US-20180244669-A1 | IMIDAZO[4,5-c] RING COMPOUNDS CONTAINING SUBSTITUTED GUANIDINE GROUPS | IFNG, IRF3, IL4 | KDM4E 1171/4885MEN1 3771/4885KMT2A 3849/4885 |
| US-10766896-B2 | Imidazo[4,5-c] ring compounds containing guanidine substituted benzamide groups | IL4, IFNG, IFNAR1 | KDM4E 1023/4885MEN1 3262/4885KMT2A 3064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.